A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12-24 month interval.

The long-acting antiphlogistics tenoxicam (Ro 12-0068, Tilcotil) and piroxicam in single daily oral doses of 20 mg are compared in a double-blind, group-comparative, randomised trial planned to last for five years. Results of 12 months' treatment of 108 patients with osteoarthritis of the hip or knee have been reported. This interim analysis focuses mainly on the 12 to 24 month interval.

Diclophenax sodium (Voltaren) in rheumatoid arthritis: a double-blind comparison with indomethacin and placebo.

Diclophenac sodium, Voltaren, has been tested against indomethacin and placebo in a four-week double-blind between-patient trial in 182 patients with rheumatoid arhritis. The ameliorating effect of Voltaren on the usual clinical parameters was comparable to that of indomethacin, while no significant changes were observed in the placebo group. Side effects during treatment with Voltaren and indomethacin appeared mainly form the gastrointestinal tract and from CNS.

Clinical evaluation of ketoprofen (Orudis) in rheumatoid arthritis: a double-blind cross-over comparison with indomethacin.

In a double-blind cross-over trial, ketoprofen was found to be as effective as indomethacin in the treatment of rheumatoid arthritis. Side-effects, particularly headache and vertigo, were less common in patients receiving ketoprofen.

Clinical evaluation of ketoprofen (19.583 R.P.) in rheumatoid arthritis. Double-blind cross-over comparison with indomethacin.

In a double-blind cross-over trial the clinical efficacy of ketoprofen (19.583 R.P.